Following his recent publication in the Lancet Respiratory Medicine, and presentation at the ERS Congress, we spoke with Prof. Liam Heaney (Queen’s University, Belfast, Northern Ireland, UK) about the composite biomarker approach to optimising steroid dosage in patients with severe asthma.
- Why is there a need for new approaches to optimising steroid dosage in people with severe asthma? (0:11)
- Could you give us a brief overview of the composite biomarker approach to optimising steroid dosage? (1:06)
- Could you tell us a little about your recent study comparing this approach with a symptomatic/risk/based algorithm? (2:23)
- What were the major findings of this study in terms of clinical and patient-reported outcomes? (4:19)
- What will be the impact of these findings on clinical practice and what future studies are planned? (6:10)
Speaker disclosure: Liam Heaney has received grant funding and taken part in advisory boards and given lectures at meetings supported by Hoffmann-La Roche–Genentech and Aerocrine. He has also taken part in asthma clinical trials sponsored by Hoffmann-La Roche–Genentech, and is an Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma, which involves industrial partnerships with a number of pharmaceutical companies, including Hoffman-La Roche and Aerocrine.
Support: Interview and filming supported by Touch Medical Media. Niche Science and Technology were given the opportunity to review the video. No changes to the video were made as a result.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In Asthma
Air pollution and respiratory diseases: Claudia Traidl-Hoffmann, EAACI 2023
Air pollution has been linked to exacerbating and causing symptoms associated with respiratory diseases, particularly impacting patients with asthma, COPD and allergic disease. touchRESPIRATORY were delighted to speak with Prof. Claudia Traidl-Hoffmann (University in Augsburg, Germany) around the symptoms associated with exposure to air pollution, the impact of air pollution on existing respiratory conditions and […]
Treatment strategies for metabolic perturbations in obesity-related asthma: Anne E. Dixon, ATS 2023
Recent epidemiological studies have shown that treatments for obesity-mediated metabolic perturbations such as GLP-1 receptors might improve symptoms in obesity-related asthma. We were delighted to speak to Prof. Anne E. Dixon (University of Vermont Larner College of Medicine, Burlington, VT, USA) around the treatment strategies associated with obesity-mediated metabolic perturbations, the data surrounding weight loss as […]
Diagnosis, management and pathophysiology of obesity-related asthma: Anne E. Dixon, ATS 2023
Obesity-related asthma is associated with poorer control and a greater number of exacerbations of asthma, which in turn reduces patient quality-of-life. We were delighted to speak to Prof. Anne E. Dixon (University of Vermont Larner College of Medicine, Burlington, VT, USA) around the difficulties in the diagnosis and management of obese asthma, the association between […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!